Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

See How to

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
13th Annual World Multispecifics Summit

13th Annual World Multispecifics Summit

Categories

Date of beginning

Tuesday, 20 September 2022

Duration

3 days

City

Danvers

Country

United States

Contact

Hanson Wade

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

The Newly Re-Branded 13th World Multispecifics Summit is the Only End-to-End Meeting Committed Solely to Advancing the Development of Bi- & Multi-Specific Therapeutics With more clinical candidates and commercial success than ever within this rapidly developing space, multi-specifics is evidently the fourth wave of drug discovery. With this, there has never been a hotter time to double down and deliver the holy grail of precision oncology as the true power of bispecifics is recognized. The 13th Annual World Multispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique target discovery, mechanistic diversity and translational science as well as novel formats, product design and manufacturability challenges faced in the bispecific field. Whatever your role or interest, you will leave the meeting with concrete methods to employ in your strategy and pipeline to convert the promise of bi- and multi-specific therapeutics into a reality for patients. With 2 tracks of unrivaled content, join with your team to catapult this community into the next generation of translational success, clinical progress, advanced mechanistic diversity, reduced toxicity and higher target affinity. Utilize the pre-conference focus day dedicated to Novel Formats and Immune Cell Modulators of multispecifics to further drive your clinical and antibody engineering strategies forward. Tickets https://go.evvnt.com/1160671-2?pid=5569Brochure https://go.evvnt.com/1160671-3?pid=5569 Prices:Conference + Focus Day - Industry Pricing USD 4646.00Conference Only - Industry Pricing USD 2999.00Conference + Focus Day - Academic & Non-Profit Pricing USD 3946.00Conference Only - Academic & Non-Profit Pricing USD 2599.00Conference + Focus Day - Service Provider Pricing USD 5546.00Conference Only - Service Provider Pricing USD 3599.00 Speakers: Alex Martinko, Co-Founder & Senior Director - Protein Science, Soteria Biotherapeutics, Alexander Haas, Head Biologics Core Technologies, Roche, Aman Singh, Associate Director, Cell Therapy Clinical Pharmacology, Modeling & Bioinformatics, Takeda, Ankita Srivastava, Vice President - Protein Sciences & Rational Design, Ichnos Sciences, Anthony Stein, Medical Doctor, City of Hope, Azra Mujic-Delic, Principal Scientist - Functional Characterization & Bioassays, Genmab, Brandon Leonard, Principal Scientific Researcher - Antibody Engineering, Genentech, Camille Grandclement, Senior Scientist, Ichnos Sciences, Chava Kimchi-Sarfat,y Deputy Associate Director - Research Office of Tissue & Advanced Therapies, CBER, FDA, Christopher Mehlin, Chief Scientific Officer & Co-founder, Link Immunotherapeutics, Daniel Pereira, Chief Scientific Officer, Invenra, David Poon, Vice President – Business Development & Alliance Management, Zymeworks, Diego Ellerman, Principal Scientific Researcher, Genentech, Erin Meermeier, Research Associate Scientist - Division of Hematology and Oncology, Mayo Clinic, Eugene Zhukovsky, Chief Scientific Officer, Ichnos Sciences, Ezio Bonvini, Chief Scientific Officer, Macrogenics, Harald Kolmar, Department Head Applied Biochemistry Technical, University of Darmstadt, Jeffrey Way, Lecturer - Department of Systems Biology, Harvard Medical School, Jonah Rainey, Vice President of Antibody Engineering and Protein Science, AlivaMab Discovery Services, Jonathan Davis, Vice President - Innovation and Strategy, Invenra, Julia Frei, Principal Scientist, Ichnos Sciences, Kalyan Pande, Associate Principal Scientist – Protein Engineering & Modalities, Merck, Liqin Liu Senior, Director of T Cell Engagers, IGM Biosciences, Martin Siegemund, Senior Scientist, Pieris Pharmaceuticals, Nimish Gera, Vice President - Biologics Research, Mythic Therapeutics, Peter Ellmark, Chief Scientific Officer, Alligator Bioscience, Pranjali Dalvi, Senior Scientist, Amgen, Prathap Shastri, Scientific Director, DMPK, Preclinical Sciences and Translational Safety, Johnson & Johnson, Rakesh Dixit, President and Head of R&D, Co-Founder, Regio Biosciences, Alexander Schinagl, PhD Chief Technology Officer, OncoOne, Shailee Patel, Researcher Beacon, Targeted Therapeutics, Shaun Lippow, Senior Director - Protein Engineering, Atreca, Suzanne Schubbert, Associate Director - Discovery Biology & Pharmacology, Xencor, Vera Sellers, Associate Director - Molecule Group, Protein & Cell Sciences Discovery & Development Technologies, EMD Serono, Wadim Matochko, Scientist Antibody Discovery, Amgen, Wei Yan, President & Chief Executive Officer, Sound Biologics, Werner Meier, Chief Scientific Officer, Revitope Oncology, Yanchen Zhou, Scientist, Amgen, Musheng Bao, Senior Director, Discovery Oncology, Harbour Biomed, Christel Iffland, PhD. VP, Antibody Technology, OmniAb, Inc. Dates and Time: Starts: Tue, Sep 20, 2022 ( 8:30 AM) and Ends: Thu, Sep 22, 2022 ( 5:00 PM) Venue details: DoubleTree by Hilton Hotel Boston North Shore, 50 Ferncroft Road, Danvers, Massachusetts, 01923, United States